Shopping Cart
- Remove All
Your shopping cart is currently empty
Ac2-26
🥰Excellent
Catalog No. TP1373Cas No. 151988-33-9
Ac2-26, an annexin A1 mimetic peptide, was able to attenuate renal inflammatory injury in a diabetic mouse model through inhibition of p38MAPK/NF-κB, as well as sepsis-induced cardiomyocyte apoptosis through the LXA4/PI3K/AKT signalling pathway, and hepatic ischaemia-reperfusion injury in mice by modulating IL-22/IL-22R1/STAT3 signalling pathway.
Ac2-26
🥰Excellent
Purity: 98.78%
Catalog No. TP1373Cas No. 151988-33-9
Ac2-26, an annexin A1 mimetic peptide, was able to attenuate renal inflammatory injury in a diabetic mouse model through inhibition of p38MAPK/NF-κB, as well as sepsis-induced cardiomyocyte apoptosis through the LXA4/PI3K/AKT signalling pathway, and hepatic ischaemia-reperfusion injury in mice by modulating IL-22/IL-22R1/STAT3 signalling pathway.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 2 mg | $86 | In Stock | |
| 5 mg | $124 | In Stock | |
| 10 mg | $198 | In Stock | |
| 25 mg | $369 | In Stock | |
| 50 mg | $539 | In Stock |
Add to Cart
Add to Quotation
Bulk & Custom
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Questions
View MoreBatch Information
Select Batch
Purity:98.78%
Contact us for more batch information
Product Introduction
Bioactivity
Chemical Properties
| Description | Ac2-26, an annexin A1 mimetic peptide, was able to attenuate renal inflammatory injury in a diabetic mouse model through inhibition of p38MAPK/NF-κB, as well as sepsis-induced cardiomyocyte apoptosis through the LXA4/PI3K/AKT signalling pathway, and hepatic ischaemia-reperfusion injury in mice by modulating IL-22/IL-22R1/STAT3 signalling pathway. |
| In vitro | Ac2-26 (1 μM, 48 h) significantly reduced cardiomyocyte death under simulated ischemic conditions[1]. |
| In vivo | In mice subjected to ischemia-reperfusion injury, Ac2-26 (1 mg/kg, i.v., just before reperfusion) reduced myocardial necrosis, inflammation (48 h), and cardiac fibrosis/apoptosis (7 days). In myocardial infarction models, continuous subcutaneous delivery of Ac2-26 (1 mg/kg/day, via osmotic pump for 1 week) delayed early cardiac dysfunction at 1 week, though no additional benefit was observed at 4 weeks. |
| Molecular Weight | 3089.43 |
| Formula | C141H210N32O44S |
| Cas No. | 151988-33-9 |
| Smiles | C([C@@H](C(N[C@@H](CC1=CC=CC=C1)C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@H](CC2=CC=C(O)C=C2)C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@H](CCCCN)C(O)=O)=O)C(C)C)=O)[C@@H](C)O)=O)CCC(N)=O)=O)[C@@H](C)C)=O)=O)CCC(O)=O)=O)CCC(N)=O)=O)CCC(O)=O)=O)CCC(O)=O)=O)CC(N)=O)=O)CCC(O)=O)=O)[C@H](CC)C)=O)=O)NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@H](CC3=CC=CC=C3)NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC(C)=O)C)=O)CCSC)=O)[C@@H](C)C)=O)CO)=O)CCC(O)=O)=O)=O)CC(C)C)=O)CCCCN)=O)CCC(N)=O)=O)C)=O)C=4C=5C(NC4)=CC=CC5 |
| Relative Density. | 1.327 g/cm3 (Predicted) |
| Sequence | Ac-Ala-Met-Val-Ser-Glu-Phe-Leu-Lys-Gln-Ala-Trp-Phe-Ile-Glu-Asn-Glu-Glu-Gln-Glu-Tyr-Val-Gln-Thr-Val-Lys |
| Sequence Short | Ac-AMVSEFLKQAWFIENEEQEYVQTVK |
Storage & Solubility Information
| Storage | keep away from moisture | store at -20°C | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||
| Solubility Information | H2O: 5 mg/mL (1.62 mM), Sonication is recommended. | ||||||||||
Solution Preparation Table | |||||||||||
H2O
| |||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% Saline/PBS/ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLSaline/PBS/ddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLSaline/PBS/ddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Sci Citations
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy Ac2-26 | purchase Ac2-26 | Ac2-26 cost | order Ac2-26 | Ac2-26 chemical structure | Ac2-26 in vivo | Ac2-26 in vitro | Ac2-26 formula | Ac2-26 molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.